Institutional investors purchased a net $850.8 thousand shares of HALO during the quarter ended December 2017. This may signal that the smart money is gaining interest in this company as the 73.57% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 1.2 Million shares of Halozyme Therapeutics Inc